The Biotech Growth Trust (BIOG)

BIOG is a specialist, pure-play investment trust focused on achieving long-term capital growth from the global biotechnology sector. Managed by OrbiMed, one ofthe world’s leading healthcare investors, the trust combines deep scientific, clinical, and financial analysis to identify companies developing innovative new medicines. Its portfolio is deliberately biased towards emerging and mid-cap biotechnology businesses, where much of the industry’s innovation sits and where valuation inefficiencies can be most pronounced. This positioning makes the trust more volatile than large-cap healthcare funds, but it is designed to capture asymmetric upside as scientific progress translates into clinical success, acquisitions, and market recovery. In this interview, co-manager Geoffrey Hsu explains how the trust navigates the high-risk, high-reward world of biotech investing. He outlines OrbiMed’s rigorous bottom-up process, blending detailed scientific due diligence with disciplined valuation and risk control, and discusses how the portfolio isconstructed to manage binary clinical events. The conversation explores why emerging biotech has been hit hardest by rising interest rates, why valuations now look compelling, and how improving funding conditions, M&A activity and a rich pipeline of clinical catalysts could drive recovery. Hsu also highlights key innovation trends – from oncology and rare diseases to gene, RNA, and cell therapies – and explains how global exposure, including China, positions the trust for the next phase of growth.